Alyeska Investment Group L.P. Purchases New Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Alyeska Investment Group L.P. acquired a new position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 3,947,369 shares of the company’s stock, valued at approximately $1,984,000.

A number of other hedge funds also recently modified their holdings of the company. Fort Sheridan Advisors LLC boosted its position in shares of Lineage Cell Therapeutics by 71.5% during the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock valued at $28,000 after acquiring an additional 23,000 shares in the last quarter. HighTower Advisors LLC boosted its holdings in Lineage Cell Therapeutics by 49.5% during the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock valued at $29,000 after purchasing an additional 19,100 shares in the last quarter. Atria Wealth Solutions Inc. bought a new stake in shares of Lineage Cell Therapeutics in the 4th quarter valued at approximately $29,000. SG Americas Securities LLC grew its stake in shares of Lineage Cell Therapeutics by 35.5% in the 4th quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after purchasing an additional 18,053 shares during the period. Finally, Wells Fargo & Company MN raised its holdings in shares of Lineage Cell Therapeutics by 33.0% in the 4th quarter. Wells Fargo & Company MN now owns 94,894 shares of the company’s stock worth $48,000 after buying an additional 23,527 shares in the last quarter. Institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Stock Down 5.1 %

Shares of NYSEAMERICAN:LCTX opened at $0.44 on Wednesday. The firm has a market cap of $95.88 million, a P/E ratio of -3.63 and a beta of 1.21. Lineage Cell Therapeutics, Inc. has a 12 month low of $0.37 and a 12 month high of $1.35. The company’s 50-day moving average price is $0.48 and its two-hundred day moving average price is $0.64.

Wall Street Analyst Weigh In

A number of analysts have weighed in on LCTX shares. Maxim Group lowered their price target on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. B. Riley reduced their price target on shares of Lineage Cell Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, March 14th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $4.20.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.